Theratechnologies (THTX) News Today → Protect Your Bank Account from China (From Behind the Markets) (Ad) Free THTX Stock Alerts $1.26 -0.04 (-3.08%) (As of 06/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 15 at 9:40 AM | americanbankingnews.comTheratechnologies Inc. (NASDAQ:THTX) Sees Significant Decrease in Short InterestJune 14 at 2:45 PM | marketbeat.comTheratechnologies Inc. (NASDAQ:THTX) Short Interest UpdateTheratechnologies Inc. (NASDAQ:THTX - Get Free Report) was the target of a significant decrease in short interest in May. As of May 31st, there was short interest totalling 15,300 shares, a decrease of 23.9% from the May 15th total of 20,100 shares. Currently, 0.1% of the company's stock are sold short. Based on an average daily trading volume, of 21,400 shares, the days-to-cover ratio is presently 0.7 days.May 27, 2024 | marketbeat.comTheratechnologies Inc. (NASDAQ:THTX) Stake Boosted by AIGH Capital Management LLCAIGH Capital Management LLC grew its stake in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 362.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,719,302 shares of the company's stock after purchasingMay 23, 2024 | finance.yahoo.comTheratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid TumorsMay 23, 2024 | globenewswire.comTheratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid TumorsMay 20, 2024 | marketbeat.comTheratechnologies Inc. (NASDAQ:THTX) Shares Purchased by Worth Venture Partners LLCWorth Venture Partners LLC raised its holdings in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 362.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 906,557 shares of the cMay 9, 2024 | globenewswire.comTheratechnologies Reports on its Annual Meeting of ShareholdersMay 2, 2024 | globenewswire.comTheratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO MeetingApril 15, 2024 | globenewswire.comTheratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of ShareholdersApril 11, 2024 | seekingalpha.comTheratechnologies Inc. (THTX) Q1 2024 Earnings Call TranscriptApril 11, 2024 | globenewswire.comTheratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | investorplace.comTHTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024April 10, 2024 | globenewswire.comTheratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024April 10, 2024 | globenewswire.comTheratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024April 8, 2024 | globenewswire.comTheratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology PlatformApril 5, 2024 | globenewswire.comTheratechnologies Appoints Elina Tea to its Board of DirectorsApril 3, 2024 | globenewswire.comTheratechnologies to Announce First Quarter 2024 Financial Results and Provide Business UpdateMarch 30, 2024 | stockhouse.comTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) PlatformMarch 28, 2024 | globenewswire.comTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ PlatformMarch 24, 2024 | investing.comTheratechnologies shifts focus, phases down preclinical researchMarch 22, 2024 | globenewswire.comTheratechnologies Announces Update on its Preclinical Oncology Research ProgramMarch 21, 2024 | globenewswire.comTheratechnologies Appoints Jordan Zwick to its Board of DirectorsMarch 21, 2024 | globenewswire.comTheratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerFebruary 29, 2024 | globenewswire.comTheratechnologies Announces the Resignation of One of Its Directors, Mr. Alain TrudeauFebruary 27, 2024 | globenewswire.comTheratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDAFebruary 21, 2024 | washingtonpost.comTheratechnologies: Fiscal Q4 Earnings SnapshotFebruary 21, 2024 | globenewswire.comTheratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 GuidanceFebruary 20, 2024 | globenewswire.comTheratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of ActionFebruary 15, 2024 | finance.yahoo.comTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerFebruary 15, 2024 | globenewswire.comTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerJanuary 24, 2024 | marketbeat.comTrading was temporarily halted for "THTX" at 06:01 AM with a stated reason of "News pending."January 23, 2024 | finance.yahoo.comTheratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License ApplicationJanuary 19, 2024 | msn.comUpcoming FDA Decision: How likely is approval for EGRIFTA MDV?January 6, 2024 | theglobeandmail.comWill This Dual-Listed Bio-Pharma Catch New Year Action?January 2, 2024 | finance.yahoo.comTheratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDAJanuary 2, 2024 | finance.yahoo.comTheratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDAJanuary 2, 2024 | markets.businessinsider.comTheratechnologies Files SBLA For Trogarzo Intramuscular Method Of Administration With FDAJanuary 2, 2024 | markets.businessinsider.comTheratechnologies Files SBLA For Trogarzo Intramuscular Method Of Administration With FDADecember 21, 2023 | msn.comTheratechnologies files for $100M mixed securities shelfDecember 21, 2023 | msn.comTheratechnologies files for $100M mixed securities shelfDecember 21, 2023 | finance.yahoo.comTheratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration StatementDecember 13, 2023 | markets.businessinsider.comFDA Approves Theratechnologies' Trogarzo 90-second IV Push Loading DoseDecember 13, 2023 | markets.businessinsider.comFDA Approves Theratechnologies' Trogarzo 90-second IV Push Loading DoseDecember 13, 2023 | markets.businessinsider.comTheratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading DoseOctober 31, 2023 | finance.yahoo.comTheratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementOctober 26, 2023 | finance.yahoo.comTheratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementOctober 26, 2023 | investing.comTheratechnologies Revises Fiscal Revenue Target Amid Continuity ConcernsOctober 24, 2023 | finance.yahoo.comTheratechnologies Announces Operational UpdateOctober 19, 2023 | financialpost.comTheratechnologies' Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIVOctober 19, 2023 | finance.yahoo.comTheratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Military's $700M "AI Software Bullet" (Ad)The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches. Get the name and stock ticker of this critical military tech firm HERE>>> THTX Media Mentions By Week THTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. THTX News Sentiment▼1.310.91▲Average Medical News Sentiment THTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. THTX Articles This Week▼41▲THTX Articles Average Week Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VTYX News Today ALDX News Today ATAI News Today PRLD News Today OMER News Today OVID News Today RENB News Today RZLT News Today IXHL News Today GBIO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:THTX) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredonly trade options on these 5-7 stocksI'm going to reveal the only 5-7 stocks you should be trading. But here's the secret - there's nothing spec...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored